|
| 37971411 | Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors. | Oncologist | 2024 |
| 37989956 | Educational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma. | Ann Surg Oncol | 2024 |
| 37971411 | Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors. | Oncologist | 2024 |
| 37535056 | A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy. | Clin Cancer Res | 2024 |
| 37989956 | Educational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma. | Ann Surg Oncol | 2024 |
| 37535056 | A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy. | Clin Cancer Res | 2024 |
| 36681606 | Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma. | Clin Genitourin Cancer | 2023 |
| 37675335 | CheckMate-915: does adjuvant CTLA-4 blockade play a role in resected melanoma? | Ann Transl Med | 2023 |
| 37790306 | Melanocortin 1 receptor (MC1R) expression as a marker of progression in melanoma. | Res Sq | 2023 |
| 37964379 | A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better. | Mol Cancer | 2023 |
| 37478171 | Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance. | Cancer Immunol Res | 2023 |
| 37476373 | Case report: Metastatic Merkel cell carcinoma presenting seven years after loco-regional disease resection of primary tumor with interval in-transit and nodal metastases. | Front Oncol | 2023 |
| 36719425 | Melanoma in pregnancy. | Abdom Radiol (NY) | 2023 |
| 36821392 | Lenvatinib or anti-VEGF in combination with anti-PD-1 differentially augments antitumor activity in melanoma. | JCI Insight | 2023 |
| 36750016 | Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. | J Clin Oncol | 2023 |
| 37382208 | Determinants of overall survival in patients with metastatic uveal melanoma. | Cancer | 2023 |
| 36739981 | Validation of the Prognostic Usefulness of the Gene Expression Profiling Test in Patients with Uveal Melanoma. | Ophthalmology | 2023 |
| 36686728 | Predictive accuracy of elevated mitotic rate on lymph node positivity and recurrence in thin melanomas. | Front Oncol | 2023 |
| 36681606 | Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma. | Clin Genitourin Cancer | 2023 |
| 37233452 | Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma. | Clin Cancer Res | 2023 |
| 36918225 | Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies. | J Immunother Cancer | 2023 |
| 36918220 | Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy. | J Immunother Cancer | 2023 |
| 37487665 | Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development. | J Immunother Cancer | 2023 |
| 37964379 | A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better. | Mol Cancer | 2023 |
| 37487665 | Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development. | J Immunother Cancer | 2023 |
| 37790306 | Melanocortin 1 receptor (MC1R) expression as a marker of progression in melanoma. | Res Sq | 2023 |
| 37675335 | CheckMate-915: does adjuvant CTLA-4 blockade play a role in resected melanoma? | Ann Transl Med | 2023 |
| 37382208 | Determinants of overall survival in patients with metastatic uveal melanoma. | Cancer | 2023 |
| 37233452 | Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma. | Clin Cancer Res | 2023 |
| 37478171 | Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance. | Cancer Immunol Res | 2023 |
| 37476373 | Case report: Metastatic Merkel cell carcinoma presenting seven years after loco-regional disease resection of primary tumor with interval in-transit and nodal metastases. | Front Oncol | 2023 |
| 36821392 | Lenvatinib or anti-VEGF in combination with anti-PD-1 differentially augments antitumor activity in melanoma. | JCI Insight | 2023 |
| 36750016 | Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. | J Clin Oncol | 2023 |
| 36719425 | Melanoma in pregnancy. | Abdom Radiol (NY) | 2023 |
| 36918225 | Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies. | J Immunother Cancer | 2023 |
| 36918220 | Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy. | J Immunother Cancer | 2023 |
| 36739981 | Validation of the Prognostic Usefulness of the Gene Expression Profiling Test in Patients with Uveal Melanoma. | Ophthalmology | 2023 |
| 36686728 | Predictive accuracy of elevated mitotic rate on lymph node positivity and recurrence in thin melanomas. | Front Oncol | 2023 |
| 34711458 | Central Nervous System Metastases. | Hematol Oncol Clin North Am | 2022 |
| 36313654 | Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance. | Front Oncol | 2022 |
| 35912544 | Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. | Pigment Cell Melanoma Res | 2022 |
| 35771575 | Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US. | JAMA Netw Open | 2022 |
| 35902131 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer. | J Immunother Cancer | 2022 |
| 35737114 | Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanoma. | Cell Mol Life Sci | 2022 |
| 36328377 | FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy. | J Immunother Cancer | 2022 |
| 35925682 | Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes. | JCI Insight | 2022 |
| 35354588 | Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. | J Immunother Cancer | 2022 |
| 35350573 | Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function. | Front Oncol | 2022 |
| 36405729 | Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab. | Front Immunol | 2022 |
| 36522538 | Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade. | NPJ Precis Oncol | 2022 |